TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Assessment of the need and potential benefits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Usability Evaluation for e-Learning Applications (UELA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Locoregional EFS
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of sub-syndromal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual Analog Scale (VAS) of Dizziness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Dizziness Handicap Inventory (DHI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of symptoms on checklist of the Sports Concussion Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: U46619 stimulated platelet P-selectin activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet-platelet aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet-monocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of benzodiazepine dose by 50% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Consecutive Increased Platelet Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sustained Increase in Platelet Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fugl-Meyer Assessment for Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in biomarker in the CSF at week 12 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to complete the first 2 weeks of active treatment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: composite of cardiac death, myocardial infarction, or target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Delay in disease diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibody Response to Hepatitis A - Participants With a Serological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to Varicella - Participants With a Serological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to Streptococcus Pneumoniae - Geometric Mean Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants With 1 or More Systemic Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With 1 or More Injection-site Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants using weekly biphosphonate who answer yes to CIQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement from baseline satisfaction score after 6 months of ibandronate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants demonstrating improvement from baseline satisfaction score after 6 months of ibandronate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pain severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Target vessel failure (TVF) at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in total score using SCI-PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite measures of Vitamin D, IL-6, Visfatin and Hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Breastfeeding Initiation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actinic Keratosis Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities of oral pazopanib
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Fatty acid composition in whole blood and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In-hospital Postoperative Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Days Abstinent From Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum LDL Cholesterol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Durable Pain Control at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Graft-Vs-Host Disease (aGVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Insomnia Severity Index (ISI) Scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: RBC Glutathion Peroxidase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelialization of the canal wall down mastoid cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: peri-papillary retinal nerve fiber layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eradication of Helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: presence of pathogenic FLCN mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: GPx-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Alpha glucosidase activity in Dry blood spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in regulatory T cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of antral follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Largest follicle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Apparent diffusion coefficient (ADC) of the adnexal mass volume (mm2/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social cooperative behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Long term neurologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: family satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response Rate of Metastatic Urothelial Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ingestive Skills Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and Urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Hypoglycemia Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: synovial fluid biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in flow-mediated dilatation (FMD) of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean level of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first biologic event (pregnancy or diagnosis with STI)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of pregnancy and sexually transmitted infections (STIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Buccal-palatal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency of the stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to Disease free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Concentrations of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child BMI Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in NPI-C Combined Agitation and Aggression Subscores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of B and B regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of COVID Ordinal Outcomes Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of the patients with Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of the Borg's scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortical vestibular evoked potential amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of blood glucose values in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic performance of elastography for thyroid cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Follow-up response rates to questionnaires (including Oxford Shoulder Score and EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participant satisfaction with the interventions: five-point ordinal scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pediatric Voice-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healing of chronic venous leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sustained PrEP adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV cure among HCV positive strata
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Provocative Concentration of Methacholine Causing 20% Fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End tidal CO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative complications requiring therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative complications requiring therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative complications requiring therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Cardiac Function: LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 6-Minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants developing postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amount of vaccine virus shed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra- and inter-observer variability of tumor target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adenoma Miss Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute change in visceral adipose tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain presence or absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swelling presence or absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic success or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological study of median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Durable Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of Radiation Delivered to 90% of Tumor Volume (D90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Volume of the Tumor Receiving the Prescription Dose (V100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of hemoglobin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normalization of signs and symptoms of acromegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Response (>=50 Percent improvement in MADRS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery by 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCI strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful analgesic proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with revision
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiogram: QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NOSE score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accurate visualization of brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stone fragments clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disappearance or Significant Alleviation of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Auscultation Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of Chest X-ray Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on CARS-M Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Smoking Cessation Behavior at 14 days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking Cessation Behavior at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventilator associated pneumonia rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with SARS-CoV-2 positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: loss of grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otoacoustic emission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Video head impulse test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness handicap inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Type and incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of growth hormone deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients clinically free of clinically significant PCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Human brain function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma MDMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life, Medical Outcomes Study short-form (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Average IFN Module Expression Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects by Treatment Arm Experiencing Any Adverse Event (AE) ≥ Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Serum D3 Vitamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gingival Crevicular fluid(GCF) LL-37 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte and monocyte subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Postoperative FLACC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Visual Acuity (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of Hedgehog pathway signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macronutrient content of expressed breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Completed 12 Cycles of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum iron pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Monthly Urine Samples That Are Negative for Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Substance use outcomes
Primary endpoint: Time to bioprosthetic valve failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in perfusion between the antrum and fundus or the artery origin and tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fundus Image Grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Cumulative incidence of cardiac erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal Intensive Care Unit admission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fasting capillary blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in fasting insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes